Corrigendum

Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age—a phase 3 extension to a randomised controlled trial” [Vaccine 35 (2017) 395–402]

Mildred A. Iro a,⇑, Matthew D. Snape a, Merryn Voysey a,b, Sena Jawad b, Adam Finn c, Paul T. Heath d, Gianni Bona e, Susanna Esposito f, Javier Diez-Domingo g, Roman Prymula h, Adefowope Odueyungbo i,1, Daniela Toneatto j, Peter Dull i,2, Andrew J. Pollard a, The European Men B Vaccine Study Group

a Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK
b Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK
c Bristol Children’s Vaccine Centre, University of Bristol, Bristol, UK
d St Georges Vaccine Institute, St George’s, University of London, London, UK
e Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy
f Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
g Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain
h Charles University Prague, School of Medicine Hradec Kralove, Czech Republic
i Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA
j GSK Vaccines S.r.l., Siena, Italy

The authors regret that since the publication of this paper, they have discovered an error in the Conclusion of the Abstract. The corrected Conclusion is listed below. The authors would also like to correct the name of Dr. Miguel Tortajada-Girbés in The European Men B vaccine study group section.

Conclusion: Waning of protective antibodies occurred 24–36 months after toddler booster regardless of age at boost. This was least marked against target strains 5/99 and M10713. A robust memory response occurred after a booster dose given at 4 years of age.

The authors would like to apologise for any inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.vaccine.2016.11.009

⇑ Corresponding author at: Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LE, UK.
E-mail address: mildred.iro@paediatrics.ox.ac.uk (M.A. Iro).
1 Current address: Alexion Pharmaceuticals Inc, Lexington, MA, USA.
2 Current address: Bill and Melinda Gates Foundation, Seattle, WA, USA.

http://dx.doi.org/10.1016/j.vaccine.2017.04.081

0264-410X/© 2017 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).